Renal Cancer


FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer (04-23-2018)

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About... Continue Reading

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma (01-25-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential... Continue Reading

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma (01-5-2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma... Continue Reading

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer (11-9-2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading

Nexavar® Is Better Tolerated than Interferon in Patients with Metastatic Renal Cell Carcinoma (03-31-2009)

In patients with untreated renal cell cancer (RCC), Nexavar® (sorafenib) results in a similar progression-free survival (PFS) to interferon, yet patients experience greater rates of tumor shrinkage and report a better quality of life (QOL) with Nexavar... Continue Reading

Nexavar® Effective in Elderly Patients with Kidney Cancer (10-22-2008)

Nexavar® Effective in Elderly Patients with Kidney Cancer Nexavar (sorafenib) provides an effective and safe treatment option for elderly patients with renal cell carcinoma (RCC), or kidney cancer. These results were recently published in the Journal... Continue Reading